Abstract
Hereditary Haemorrhagic Telangiectasia (HHT) or Rendu-Osler-Weber syndrome, is an autosomal dominant rare disease characterized by localized angiodysplasia. This is manifested as epistaxis, mucocutaneous and gastrointestinal telangiectases, and arteriovenous malformations in the pulmonary, cerebral or hepatic circulation. The prevalence is between 1 in 5,000 to 8,000, although it is higher in some regions.
The most frequent clinical manifestation of HHT is epistaxis, normally from light to moderate from the 4th decade of life. However, many patients show severe epistaxis which may interfere with their quality of life. The epistaxis is due to telangiectasia on the nasal mucosa. These are focally dilated postcapilar venules, which in advanced phases show many layers of smooth muscle cells without elastic fibers, and very frequently directly connect with dilated arterioles. As a consequence of these vascular alterations, telangiectases are very sensitive to slight trauma and even to the friction with the air when breathing, which gives rise to nose bleeds.
Unfortunately, there is no optimal pharmacological treatment for the epistaxis in HHT. The use of antifibrinolytic agents for the treatment of HHT has been studied recently by our group as an effective relief for nasal and gastric haemorrhages. This work represents a systematic review and the begining of a systematic laboratory work we are now conducting in our lab to screen for “orphan drugs” as therapeutic agents in HHT. In this context, the use of hormones, immunosuppresants and anti-angiogenic agents are under preclinical study in our laboratory.
Keywords: HHT, endoglin, ACVLR1/ALK1, TGF-beta, antifibrinolytic coagulants, immunosuppressant agents, antitumoral drugs, anti-angiogenic agents
Current Vascular Pharmacology
Title: A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT)
Volume: 8 Issue: 4
Author(s): Roberto Zarrabeitia, Virginia Albinana, Matilde Salcedo, B. Senaris-Gonzalez, Jose-Luis Fernandez-Forcelledo and Luisa-Maria Botella
Affiliation:
Keywords: HHT, endoglin, ACVLR1/ALK1, TGF-beta, antifibrinolytic coagulants, immunosuppressant agents, antitumoral drugs, anti-angiogenic agents
Abstract: Hereditary Haemorrhagic Telangiectasia (HHT) or Rendu-Osler-Weber syndrome, is an autosomal dominant rare disease characterized by localized angiodysplasia. This is manifested as epistaxis, mucocutaneous and gastrointestinal telangiectases, and arteriovenous malformations in the pulmonary, cerebral or hepatic circulation. The prevalence is between 1 in 5,000 to 8,000, although it is higher in some regions.
The most frequent clinical manifestation of HHT is epistaxis, normally from light to moderate from the 4th decade of life. However, many patients show severe epistaxis which may interfere with their quality of life. The epistaxis is due to telangiectasia on the nasal mucosa. These are focally dilated postcapilar venules, which in advanced phases show many layers of smooth muscle cells without elastic fibers, and very frequently directly connect with dilated arterioles. As a consequence of these vascular alterations, telangiectases are very sensitive to slight trauma and even to the friction with the air when breathing, which gives rise to nose bleeds.
Unfortunately, there is no optimal pharmacological treatment for the epistaxis in HHT. The use of antifibrinolytic agents for the treatment of HHT has been studied recently by our group as an effective relief for nasal and gastric haemorrhages. This work represents a systematic review and the begining of a systematic laboratory work we are now conducting in our lab to screen for “orphan drugs” as therapeutic agents in HHT. In this context, the use of hormones, immunosuppresants and anti-angiogenic agents are under preclinical study in our laboratory.
Export Options
About this article
Cite this article as:
Zarrabeitia Roberto, Albinana Virginia, Salcedo Matilde, Senaris-Gonzalez B., Fernandez-Forcelledo Jose-Luis and Botella Luisa-Maria, A Review on Clinical Management and Pharmacological Therapy on Hereditary Haemorrhagic Telangiectasia (HHT), Current Vascular Pharmacology 2010; 8 (4) . https://dx.doi.org/10.2174/157016110791330771
DOI https://dx.doi.org/10.2174/157016110791330771 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Advancements in Arterial Stiffness: Novel Therapeutic Frontiers
Arterial stiffness, a hallmark of cardiovascular disease, poses significant challenges in contemporary healthcare. This thematic issue delves into the multifaceted landscape of arterial stiffness and explores cutting-edge therapeutic interventions aimed at mitigating its adverse effects. Within these pages, readers will find a comprehensive overview of the mechanisms underlying arterial stiffness, ...read more
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Towards Characteristics of Photodynamic Drugs Specifically Aimed at Microvascular Diseases
Mini-Reviews in Medicinal Chemistry Low Estimated Glomerular Filtration Rate is Associated with High Recurrence Rate and Poor Prognosis of Hemorrhage Stroke
Current Neurovascular Research A Role for TGF-β Signaling in Neurodegeneration: Evidence from Genetically Engineered Models
Current Alzheimer Research GABAA Receptors in Normal Development and Seizures: Friends or Foes?
Current Neuropharmacology SHP-2 Regulates Growth Factor Dependent Vascular Signalling and Function
Mini-Reviews in Medicinal Chemistry Genetics of Congenital Heart Disease
Current Cardiology Reviews Is the Hepatic Factor a miRNA that Maintains the Integrity of Pulmonary Microvasculature by Inhibiting the Vascular Endothelial Growth Factor?
Current Cardiology Reviews The Impact of Type 2 Diabetes on Women’s Health and Well-being During Their Reproductive Years: A Mixed-methods Systematic Review
Current Diabetes Reviews Aptamers Against Cell Surface Receptors: Selection, Modification and Application
Current Medicinal Chemistry Impact of Pulmonary Vascular Resistances in Heart Transplantation for Congenital Heart Disease
Current Cardiology Reviews Inhibition of RET Activated Pathways: Novel Strategies for Therapeutic Intervention in Human Cancers
Current Pharmaceutical Design Proteasome Inhibitors and Modulators of Angiogenesis in Multiple Myeloma
Current Medicinal Chemistry Do Not Say Ever Never More: The Ins and Outs of Antiangiogenic Therapies
Current Pharmaceutical Design Recurrent Pregnancy Losses
Current Women`s Health Reviews Neonatal Hypertension: An Underdiagnosed Condition, A Review Article
Current Hypertension Reviews A Pictorial Review of Intracranial Haemorrhage Revisited
Current Medical Imaging Orthotopic Heart Transplantation in Patients with Univentricular Physiology
Current Cardiology Reviews New Molecules as Drug Candidates for the Treatment of Upper and Lower GI Tract Ulcers
Current Pharmaceutical Design Current Outcomes and Considerations in Hypoplastic Left Heart Syndrome
Current Pediatric Reviews BMPS and Liver: More Questions than Answers
Current Pharmaceutical Design